Report Detail

Request for Sample of this report

Pharma & Healthcare COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

  • RnM4074218
    • |
  • 23 June, 2020
    • |
  • Global
    • |
  • 117 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Inactivated Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Inactivated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Inactivated Vaccine market is segmented into
Children
Adult

Segment by Application, the Inactivated Vaccine market is segmented into
Hospital
Medical Center

Regional and Country-level Analysis
The Inactivated Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Inactivated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Inactivated Vaccine Market Share Analysis
Inactivated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Inactivated Vaccine business, the date to enter into the Inactivated Vaccine market, Inactivated Vaccine product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson & Johnson (U.S.)
MedImmune (U.S.)
Merck & Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)


1 Study Coverage

  • 1.1 Inactivated Vaccine Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Inactivated Vaccine Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Inactivated Vaccine Market Size Growth Rate by Type
    • 1.4.2 Children
    • 1.4.3 Adult
  • 1.5 Market by Application
    • 1.5.1 Global Inactivated Vaccine Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Medical Center
  • 1.6 Coronavirus Disease 2019 (Covid-19): Inactivated Vaccine Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Inactivated Vaccine Industry
      • 1.6.1.1 Inactivated Vaccine Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Inactivated Vaccine Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Inactivated Vaccine Market Size Estimates and Forecasts
    • 2.1.1 Global Inactivated Vaccine Revenue 2015-2026
    • 2.1.2 Global Inactivated Vaccine Sales 2015-2026
  • 2.2 Inactivated Vaccine Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Inactivated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Inactivated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Inactivated Vaccine Competitor Landscape by Players

  • 3.1 Inactivated Vaccine Sales by Manufacturers
    • 3.1.1 Inactivated Vaccine Sales by Manufacturers (2015-2020)
    • 3.1.2 Inactivated Vaccine Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Inactivated Vaccine Revenue by Manufacturers
    • 3.2.1 Inactivated Vaccine Revenue by Manufacturers (2015-2020)
    • 3.2.2 Inactivated Vaccine Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2019
    • 3.2.5 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Inactivated Vaccine Price by Manufacturers
  • 3.4 Inactivated Vaccine Manufacturing Base Distribution, Product Types
    • 3.4.1 Inactivated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Inactivated Vaccine Product Type
    • 3.4.3 Date of International Manufacturers Enter into Inactivated Vaccine Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Inactivated Vaccine Market Size by Type (2015-2020)
    • 4.1.1 Global Inactivated Vaccine Sales by Type (2015-2020)
    • 4.1.2 Global Inactivated Vaccine Revenue by Type (2015-2020)
    • 4.1.3 Inactivated Vaccine Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Inactivated Vaccine Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Inactivated Vaccine Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Inactivated Vaccine Revenue Forecast by Type (2021-2026)
    • 4.2.3 Inactivated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Inactivated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Inactivated Vaccine Market Size by Application (2015-2020)
    • 5.1.1 Global Inactivated Vaccine Sales by Application (2015-2020)
    • 5.1.2 Global Inactivated Vaccine Revenue by Application (2015-2020)
    • 5.1.3 Inactivated Vaccine Price by Application (2015-2020)
  • 5.2 Inactivated Vaccine Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Inactivated Vaccine Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Inactivated Vaccine Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Inactivated Vaccine Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Inactivated Vaccine by Country
    • 6.1.1 North America Inactivated Vaccine Sales by Country
    • 6.1.2 North America Inactivated Vaccine Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Inactivated Vaccine Market Facts & Figures by Type
  • 6.3 North America Inactivated Vaccine Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Inactivated Vaccine by Country
    • 7.1.1 Europe Inactivated Vaccine Sales by Country
    • 7.1.2 Europe Inactivated Vaccine Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Inactivated Vaccine Market Facts & Figures by Type
  • 7.3 Europe Inactivated Vaccine Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Inactivated Vaccine by Region
    • 8.1.1 Asia Pacific Inactivated Vaccine Sales by Region
    • 8.1.2 Asia Pacific Inactivated Vaccine Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Inactivated Vaccine Market Facts & Figures by Type
  • 8.3 Asia Pacific Inactivated Vaccine Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Inactivated Vaccine by Country
    • 9.1.1 Latin America Inactivated Vaccine Sales by Country
    • 9.1.2 Latin America Inactivated Vaccine Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Inactivated Vaccine Market Facts & Figures by Type
  • 9.3 Central & South America Inactivated Vaccine Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Inactivated Vaccine by Country
    • 10.1.1 Middle East and Africa Inactivated Vaccine Sales by Country
    • 10.1.2 Middle East and Africa Inactivated Vaccine Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Type
  • 10.3 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Astellas Pharma (Japan)
    • 11.1.1 Astellas Pharma (Japan) Corporation Information
    • 11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
    • 11.1.5 Astellas Pharma (Japan) Recent Development
  • 11.2 CSL Limited (Australia)
    • 11.2.1 CSL Limited (Australia) Corporation Information
    • 11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue
    • 11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 CSL Limited (Australia) Inactivated Vaccine Products Offered
    • 11.2.5 CSL Limited (Australia) Recent Development
  • 11.3 Emergent BioSolutions (U.S.)
    • 11.3.1 Emergent BioSolutions (U.S.) Corporation Information
    • 11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue
    • 11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Emergent BioSolutions (U.S.) Inactivated Vaccine Products Offered
    • 11.3.5 Emergent BioSolutions (U.S.) Recent Development
  • 11.4 GlaxoSmithKline (U.K.)
    • 11.4.1 GlaxoSmithKline (U.K.) Corporation Information
    • 11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue
    • 11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 GlaxoSmithKline (U.K.) Inactivated Vaccine Products Offered
    • 11.4.5 GlaxoSmithKline (U.K.) Recent Development
  • 11.5 Johnson & Johnson (U.S.)
    • 11.5.1 Johnson & Johnson (U.S.) Corporation Information
    • 11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue
    • 11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Johnson & Johnson (U.S.) Inactivated Vaccine Products Offered
    • 11.5.5 Johnson & Johnson (U.S.) Recent Development
  • 11.6 MedImmune (U.S.)
    • 11.6.1 MedImmune (U.S.) Corporation Information
    • 11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue
    • 11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 MedImmune (U.S.) Inactivated Vaccine Products Offered
    • 11.6.5 MedImmune (U.S.) Recent Development
  • 11.7 Merck & Co (U.S.)
    • 11.7.1 Merck & Co (U.S.) Corporation Information
    • 11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue
    • 11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Merck & Co (U.S.) Inactivated Vaccine Products Offered
    • 11.7.5 Merck & Co (U.S.) Recent Development
  • 11.8 Pfizer (U.S.)
    • 11.8.1 Pfizer (U.S.) Corporation Information
    • 11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue
    • 11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Pfizer (U.S.) Inactivated Vaccine Products Offered
    • 11.8.5 Pfizer (U.S.) Recent Development
  • 11.9 Sanofi Pasteur (France)
    • 11.9.1 Sanofi Pasteur (France) Corporation Information
    • 11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue
    • 11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Sanofi Pasteur (France) Inactivated Vaccine Products Offered
    • 11.9.5 Sanofi Pasteur (France) Recent Development
  • 11.10 Serum Institute of India Pvt (India)
    • 11.10.1 Serum Institute of India Pvt (India) Corporation Information
    • 11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue
    • 11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Serum Institute of India Pvt (India) Inactivated Vaccine Products Offered
    • 11.10.5 Serum Institute of India Pvt (India) Recent Development
  • 11.1 Astellas Pharma (Japan)
    • 11.1.1 Astellas Pharma (Japan) Corporation Information
    • 11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
    • 11.1.5 Astellas Pharma (Japan) Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Inactivated Vaccine Market Estimates and Projections by Region
    • 12.1.1 Global Inactivated Vaccine Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Inactivated Vaccine Revenue Forecast by Regions 2021-2026
  • 12.2 North America Inactivated Vaccine Market Size Forecast (2021-2026)
    • 12.2.1 North America: Inactivated Vaccine Sales Forecast (2021-2026)
    • 12.2.2 North America: Inactivated Vaccine Revenue Forecast (2021-2026)
    • 12.2.3 North America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Inactivated Vaccine Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Inactivated Vaccine Sales Forecast (2021-2026)
    • 12.3.2 Europe: Inactivated Vaccine Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Inactivated Vaccine Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Inactivated Vaccine Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Inactivated Vaccine Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Inactivated Vaccine Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Inactivated Vaccine Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Inactivated Vaccine Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Inactivated Vaccine Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Inactivated Vaccine Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Inactivated Vaccine Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Inactivated Vaccine Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Inactivated Vaccine Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Inactivated Vaccine Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Inactivated Vaccine Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Summary:
    Get latest Market Research Reports on COVID-19 Impact on Global Inactivated Vaccine. Industry analysis & Market Report on COVID-19 Impact on Global Inactivated Vaccine is a syndicated market report, published as COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Inactivated Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,900.00
    		$5,850.00
    		$7,800.00
    		3,065.40
    		4,598.10
    		6,130.80
    		3,603.60
    		5,405.40
    		7,207.20
    		610,662.00
    		915,993.00
    		1,221,324.00
    		324,831.00
    		487,246.50
    		649,662.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo